Organic Active Ingredients TRIZ Cases

Amorphous dasatinib dispersions maintain bioavailability despite acid-reducing agents and allow crushable oral dosing for swallowing difficulties.

Preformed crystalline Z-endoxifen bypasses CYP2D6 variability and tamoxifen side effects while improving stable plasma exposure in hormone-dependent disorders.

WWOX SNP PCR genotyping helps identify cancer patients likely to respond to arginine deprivation therapy before ASS1-linked resistance emerges.

An adjustable minus-lens mouse model reproduces axial myopia features and helps screen ER stress suppressants that slow myopia progression.

A bispecific PD-L1/CD137 antibody combines dual target binding in one therapy to boost T-cell activity while reducing separate dosing burden.

Stable ATR inhibitor crystal forms resist light, heat, and humidity while preserving in vivo efficacy for ATR-related cancer treatment.

Single nanoparticles co-deliver siRNA and mRNA to coordinate gene suppression and protein expression with less delivery complexity.

Engineered ketoreductases enable stereoselective phenylephrine production with high conversion, minimal substrate decomposition, and >99% ee.

A dibenzoxazepinone small molecule boosts immune cell activation by inhibiting PD-1/PD-L1 and ERK signaling while reducing tumor growth.

Targeting the ERK1/2 substrate docking site helps curb airway remodeling while reducing off-target toxicity and resistance.

A biphasic drospirenone dosing regimen treats endometriosis pain, reduces bleeding, and provides estrogen-free contraception with amenorrhea induction.

A bioadhesive vaginal danazol formulation localizes drug to peritoneal tissue, reducing systemic exposure and endometriosis pain.

Specific niraparib dosing achieves therapeutic tumor concentrations for primary and metastatic brain cancer, with potential benefit in radiation combinations.

Sugar-functionalized nanoparticle carriers balance biocompatibility, cellular uptake, and transfection for nucleic acid delivery.

Novel imidazopyridine derivatives inhibit LSD1 while improving selectivity to limit normal-cell toxicity and resistance in cancer treatment.

Combining selective PARP1 and ATR inhibitors boosts DNA damage and anti-tumor activity to address resistance in hard-to-treat cancers.

A five-strain probiotic composition helps relieve chemotherapy-induced diarrhea by restoring gut flora, inhibiting pathogens, and repairing intestinal barriers.

Chemical conversion of bovine heparin preserves complement and P-selectin inhibition while lowering anti-factor IIa activity and bleeding risk.

A combined saffron, ashwagandha, and methylcobalamin formulation improves mood support while balancing multi-ingredient dosage complexity.

A nitrogen-containing chain lipid improves nucleic acid delivery by enabling stable lipid nanoparticles with effective cellular uptake and lower phospholipid content.

A combined topical formulation improves hair growth and hair loss treatment while reducing scalp irritation and frequent application.

Novel heterocyclic serotonergic compounds aim to preserve mental health efficacy while lowering psychedelic adverse events and regulatory barriers.

Electric-pulse DNA delivery boosts in vivo protein expression without viral vectors, reducing immunogenicity, dosing frequency, and cost.

Early psilocybin dosing is used to limit ischemic brain injury by reducing infarction and inflammation while supporting BDNF-linked recovery.

Stabilizing HIF with vadadustat helps treat viral infection, acute lung injury, and organ damage while reducing mortality and morbidity.

Salt-form artemisinin derivatives improve solubility, storage stability, and ocular absorption for eye drops and other liquid treatments.

Beta-cyclodextrin and poloxamer turn poorly soluble CBD into an aqueous composition with better bioavailability and cytokine reduction.

Small-molecule benzimidazole therapy promotes stem-cell self-renewal and slows cellular ageing, with optional PDE 5 synergy for age-related disease control.

Amorphous spray-granulated AKR1C3-dependent KARS inhibitor compositions improve oral bioavailability and stability while helping limit toxicity.

N-acyl glucosamine prodrugs improve oral bioavailability and stability while enhancing bone density, microarchitecture, and cartilage formation.

Phenolic acid derivatives suppress post-ischemic inflammation to reduce infarction volume and improve neurological recovery after stroke.

Targeting the active KRAS G12C form with tetrahydropyridopyrimidine derivatives improves inhibitor potency and helps overcome cancer resistance.

Ca2+ adsorption on SNA phosphate backbones improves oligonucleotide uptake and nuclease resistance for stronger gene modulation.

Selective piperidine carboxamide azaindane derivatives inhibit CGRP receptors to treat migraine with fewer cardiovascular risks and side effects.

Irreversible menin inhibitors bond to Cys329 to block menin-MLL interaction, improving potency and cellular specificity in disease treatment.

Substituted bicyclic heterocyclic compounds target Huntington's disease mechanisms to improve treatment efficacy with small-molecule therapy.

Oral LDH inhibitors are engineered to improve potency, cellular penetration, and liver exposure while reducing oxalate production in hyperoxaluria.

TAOK1 inhibition helps prevent anthracycline-related myocardial cell death while avoiding the carcinogenic risk and efficacy loss linked to dexrazoxane.

DGKα/DGKζ inhibition sustains DAG signaling to reverse T cell anergy, boost proliferation, and strengthen antitumor immunity.

Macrocyclic indazole compounds target EGFR, ALK, PIM, and CLK pathways to overcome mutation-driven resistance and extend disease control.

Sub-10 nm ATP-functionalized metallic nanoclusters collapse dormant bacterial and cancer cell survival pathways, helping overcome resistance and biofilms.

Light-triggered miniSOG polymerization on targeted neuronal membranes enables precise, long-term excitability control with reduced circuit off-target effects.

A mono- and di-rhamnolipid blend helps coordinate wound-healing gene expression to speed repair in acute and chronic wounds.

These HSPA5-targeting benzene sulfonamide thiazoles trigger early ER stress to inhibit cancer cell growth and induce apoptosis.

A hydrophilic polymer and alkalizing agents keep meloxicam soluble in acidic conditions, shortening Tmax and improving acute pain relief.

PolyT termination sequences truncate guide RNAs to curb off-target CRISPR activity and improve precision in target gene regulation.

Sequence-specific oligomeric agents lower APOE RNA and ApoE protein to help reduce cognitive decline, memory loss, and amyloid plaques.

A non-aqueous intranasal olanzapine formulation uses dodecyl maltoside for rapid absorption comparable to injection without needles.

An embedded alkalizer in a hydrophilic carrier matrix keeps mangiferin soluble across gastric pH, improving oral bioavailability and efficacy.

By degrading MDM2 instead of only blocking it, Compound A sustains p53 activation and overcomes feedback-limited cancer therapy.